Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Sodium-glucose co-transporter 2 inhibitors and bladder cancer - a causal association or detection bias? An international multicenter cohort study.

Funder: Canadian Institutes of Health Research

Funding period
CAD 100 K
USD 76 K
Funding amount
Abstract
Type 2 diabetes is one of the fastest growing diseases in Canada, with approximately 60,000 new patients diagnosed each year. In recent years, there have been major advancements in the treatment of type 2 diabetes with the discovery of new drug classes, such as the sodium-glucose co-transporter 2 (SGLT2) inhibitors. SGLT2 inhibitors have become increasingly popular, as they effectively lower blood sugar levels without the side effects of other antidiabetic drugs. However, these drugs have been associated with frequent urinary tract infections, and there are signals from trials that they may be associated with an increased risk of bladder cancer. To date, however, no study has been conducted in the real-world setting to assess this association. Thus, to address this gap in knowledge, I will conduct a multicenter cohort study among patients with type 2 diabetes using data sources from Canada, Europe and the Middle East. As a possible association may be explained by increased screening of the urinary tract, this international study will be specifically designed to differentiate between a possible biological effect and detection bias. Thus, this study will provide much needed information on the safety of SGLT2 inhibitors, and will be of value to regulatory agencies, physicians, and patients.
Similar projects All >
Sorted by: Start Date
Project list item
SGLT-2 Inhibitors and Early Bladder Cancer Events: An International Multi-Centre Study

Canadian Institutes of Health Research to Laurent Azoulay, Elisabetta Patorno, Oriana Hoi Yun Yu, Sebastian Schneeweiss, Robert William Platt, Blanaid Hicks, Lysanne Campeau, Devin Abrahami

USD 88,269
2020 - 2022
Project list item
CD40 agonism for the treatment of bladder cancer

National Cancer Institute to CHRISTOPHER STUART GARRIS

USD 64,554
2020 - 2023
Project list item
Analysis of the effect of IDO inhibition on activation of the aryl hydrocarbon receptor pathway in bladder cancer

São Paulo Research Foundation to Humberto Dellê

 
2020 - 2021
Project list item
A canine model for human high-risk non-muscle invasive human bladder cancer – molecular and environmental considerations.

V Foundation for Cancer Research to Matthew Breen

USD 500,000
2019 - 2021
Project list item
Chemotherapy plus PD-1 blockade as bladder-sparing treatment for muscle-invasive bladder cancer

V Foundation for Cancer Research to Matthew D Galsky

USD 600,000
2019 - 2022

System

Categories
  • FOR (ANZSRC)

    1117 Public Health and Health Services

  • RCDC

    Diabetes

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Patient Safety

  • RCDC

    Prevention

  • RCDC

    Urologic Diseases

  • HRCS HC

    Metabolic and Endocrine

  • HRCS HC

    Cancer

  • HRCS RAC

    5.1 Pharmaceuticals

  • Health Research Areas

    Population & Society

  • Broad Research Areas

    Public Health